TherapeuticsMD (NASDAQ:TXMD) PT Lowered to $6.00 at JPMorgan Chase & Co.

Share on StockTwits

TherapeuticsMD (NASDAQ:TXMD) had its price target decreased by research analysts at JPMorgan Chase & Co. from $8.00 to $6.00 in a research report issued on Tuesday, The Fly reports. The firm currently has a “buy” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 136.22% from the stock’s current price.

TXMD has been the subject of several other research reports. ValuEngine downgraded shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a report on Wednesday, February 20th. Oppenheimer set a $14.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a report on Monday, February 11th. Zacks Investment Research downgraded shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Thursday, February 28th. BidaskClub raised shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a report on Wednesday, March 6th. Finally, Jefferies Financial Group dropped their price objective on shares of TherapeuticsMD from $5.00 to $4.00 and set a “hold” rating for the company in a report on Tuesday, May 7th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $11.16.

Shares of TXMD traded up $0.16 during midday trading on Tuesday, hitting $2.54. 84,953 shares of the company traded hands, compared to its average volume of 3,187,358. TherapeuticsMD has a 52 week low of $2.21 and a 52 week high of $7.42. The company has a market capitalization of $759.85 million, a PE ratio of -4.37 and a beta of 2.14. The company has a quick ratio of 3.28, a current ratio of 3.39 and a debt-to-equity ratio of 1.26.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Monday, May 6th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01. TherapeuticsMD had a negative net margin of 907.71% and a negative return on equity of 159.71%. The business had revenue of $3.95 million during the quarter, compared to the consensus estimate of $5.96 million. During the same quarter in the prior year, the firm earned ($0.11) EPS. The business’s revenue was up 4.8% on a year-over-year basis. As a group, sell-side analysts expect that TherapeuticsMD will post -0.64 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in TXMD. FMR LLC raised its position in shares of TherapeuticsMD by 50.1% during the 4th quarter. FMR LLC now owns 18,088,341 shares of the company’s stock valued at $68,917,000 after buying an additional 6,038,353 shares in the last quarter. Frontier Capital Management Co. LLC raised its position in shares of TherapeuticsMD by 291.5% during the 1st quarter. Frontier Capital Management Co. LLC now owns 5,857,096 shares of the company’s stock valued at $28,524,000 after buying an additional 4,360,963 shares in the last quarter. Rubric Capital Management LP raised its position in shares of TherapeuticsMD by 203.6% during the 1st quarter. Rubric Capital Management LP now owns 4,690,970 shares of the company’s stock valued at $22,845,000 after buying an additional 3,145,742 shares in the last quarter. Millennium Management LLC raised its position in shares of TherapeuticsMD by 590.6% during the 4th quarter. Millennium Management LLC now owns 2,848,750 shares of the company’s stock valued at $10,854,000 after buying an additional 2,436,259 shares in the last quarter. Finally, Daruma Capital Management LLC raised its position in shares of TherapeuticsMD by 11.8% during the 1st quarter. Daruma Capital Management LLC now owns 7,111,035 shares of the company’s stock valued at $34,631,000 after buying an additional 750,235 shares in the last quarter. Hedge funds and other institutional investors own 78.93% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Further Reading: Cost of Equity For A Business, Investors

The Fly

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.